These studies first initiated in 1962 with the specific objective of providing additional evidence of systemic safety to add to the then sparse data provided by Rowe, Spencer and Bass (532) . The body of animal safety information developed by Ashley and co-workers adds immeasurably to the history of preclinical safety associated with DOW CORNING 360 Medical Grade Fluid administration. The absence of significant untoward symptomatology, or of any significant treatment related tissue pathology, are supportive to the findings of other investigators discussed in this submission. Seen in its critical dimensions, the findings in rodents, and in the subhaman primates, correlate in all respects with the observations derived from the extensive human experience available. The data have been prepared in a form to permit examination of elements with respect.